Paul Tuite

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7857666/publications.pdf

Version: 2024-02-01

56	4,612	27 h-index	51
papers	citations		g-index
60	60	60	5914
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	White matter microstructure in Parkinson's disease with and without elevated rapid eye movement sleep muscle tone. Brain Communications, 2022, 4, fcac027.	1.5	3
2	Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson's Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T. Metabolites, 2021, 11, 145.	1.3	11
3	Hatha yoga training improves standing balance but not gait in Parkinson's disease. Sports Medicine and Health Science, 2020, 2, 80-88.	0.7	12
4	Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Diseaseâ€"A Pilot Study. Journal of Clinical Pharmacology, 2020, 60, 744-750.	1.0	25
5	Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism and Related Disorders, 2019, 65, 178-183.	1.1	20
6	McLeod syndrome: Five new pedigrees with novel mutations. Parkinsonism and Related Disorders, 2019, 64, 293-299.	1.1	9
7	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	4.9	108
8	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	1.1	7
9	Preliminary N-acetylcysteine results for LDN 6722 - Role of oxidative stress and inflammation in Gaucher disease type 1: Potential use of antioxidant anti-inflammatory medications. Molecular Genetics and Metabolism, 2019, 126, S82.	0.5	2
10	Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson's disease: a pilot randomized controlled trial. Pilot and Feasibility Studies, 2018, 4, 162.	0.5	48
11	White matter measures correlate with essential tremor severity—A pilot diffusion tensor imaging study. Brain and Behavior, 2018, 8, e01039.	1.0	12
12	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288.	2.2	122
13	Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD). Brain Sciences, 2017, 7, 68.	1.1	16
14	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 2016, 31, 924-932.	2.2	48
15	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. Translational Research, 2016, 175, 4-16.	2.2	23
16	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
17	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics, 2013, 14, 11-22.	0.7	131
18	N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases. Clinical Neuropharmacology, 2013, 36, 103-106.	0.2	165

#	Article	IF	Citations
19	Magnetization transfer and adiabatic R1ϕMRI in the brainstem of Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 623-625.	1.1	14
20	Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS. PLoS ONE, 2012, 7, e30918.	1.1	156
21	T1ϕand T2ϕMRI in the evaluation of Parkinson's disease. Journal of Neurology, 2010, 257, 964-968.	1.8	64
22	The effect of dopamine replacement therapy on haptic sensitivity in Parkinson's disease. Journal of Neurology, 2010, 257, 1992-1998.	1.8	24
23	Inferior Olive Response to Passive Tactile and Visual Stimulation with Variable Interstimulus Intervals. Cerebellum, 2010, 9, 598-602.	1.4	13
24	Proprioception and Motor Control in Parkinson's Disease. Journal of Motor Behavior, 2009, 41, 543-552.	0.5	248
25	Adenosine A _{2A} receptor antagonist istradefylline (KWâ€6002) reduces "offâ€time in Parkinson's disease: A doubleâ€blind, randomized, multicenter clinical trial (6002â€USâ€005). Annals of Neurology, 2008, 63, 295-302.	2.8	333
26	ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. Journal of Immunological Methods, 2008, 336, 22-29.	0.6	53
27	Altered Diffusion in the Frontal Lobe in Parkinson Disease. American Journal of Neuroradiology, 2008, 29, 501-505.	1.2	177
28	Gaze Control and Foot Kinematics During Stair Climbing: Characteristics Leading to Fall Risk in Progressive Supranuclear Palsy. Physical Therapy, 2008, 88, 240-250.	1.1	16
29	Haptic Perception of Object Curvature in Parkinson's Disease. PLoS ONE, 2008, 3, e2625.	1.1	39
30	Parkinsonism: A Review-of-Systems Approach to Diagnosis. Seminars in Neurology, 2007, 27, 113-122.	0.5	15
31	Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms. American Journal of Human Genetics, 2007, 80, 769-778.	2.6	68
32	Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Movement Disorders, 2007, 22, 334-340.	2.2	128
33	Selective impairments in implicit learning in Parkinson's disease. Brain Research, 2007, 1137, 104-110.	1.1	46
34	Gaze-shift strategies during functional activity in progressive supranuclear palsy. Experimental Brain Research, 2007, 178, 351-362.	0.7	6
35	Interval timing and Parkinson's disease: heterogeneity in temporal performance. Experimental Brain Research, 2007, 184, 233-248.	0.7	108
36	The perception of passive motion in Parkinson's disease. Journal of Neurology, 2007, 254, 655-663.	1.8	104

#	Article	IF	CITATIONS
37	Erratum to "Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery―[Parkinsonism and Related Disorders 11 (2005) 247–252]. Parkinsonism and Related Disorders, 2006, 12, 121.	1.1	2
38	Depth perception in cerebellar and basal ganglia disease. Experimental Brain Research, 2006, 175, 165-176.	0.7	23
39	Association between vestibuloocular reflex suppression during smooth movements of the head and attention deficit in progressive supranuclear palsy. Movement Disorders, 2006, 21, 910-915.	2.2	7
40	Clinical and Pathologic Evidence of Corticobasal Degeneration and Progressive Supranuclear Palsy in Familial Tauopathy. Archives of Neurology, 2005, 62, 1453.	4.9	29
41	Constraint-induced movement therapy in Parkinson's disease. Movement Disorders, 2005, 20, 910-911.	2.2	6
42	Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. Parkinsonism and Related Disorders, 2005, $11,247-252$.	1.1	58
43	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. Brain, 2004, 127, 1252-1268.	3.7	134
44	The evaluation and management of patients with neuroleptic malignant syndrome. Neurologic Clinics, 2004, 22, 389-411.	0.8	113
45	Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia. Brain, 2003, 126, 2312-2322.	3.7	212
46	Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opinion on Investigational Drugs, 2003, 12, 1335-1352.	1.9	28
47	A Controlled Trial of Rasagiline in Early Parkinson Disease. Archives of Neurology, 2002, 59, 1937.	4.9	559
48	Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Annals of Neurology, 2002, 51, 625-630.	2.8	212
49	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Annals of Neurology, 1997, 42, 292-299.	2.8	508
50	POEMS syndrome in a 24-year-old man associated with vitamin B12 deficiency and a solitary lytic bone lesion., 1997, 20, 1454-1456.		6
51	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. Movement Disorders, 1996, 11, 448-449.	2.2	16
52	Cerebral Vein Thrombosis due to Hereditary Antithrombin III Deficiency. Canadian Journal of Neurological Sciences, 1993, 20, 158-161.	0.3	11
53	Magnetic resonance imaging (MRI) methods in Parkinson's disease. , 0, , 1-13.		1
54	Imaging iron in Parkinson's disease. , 0, , 14-25.		0

#	Article	IF	CITATIONS
55	Motor Parkinson's disease and structure. , 0, , 26-43.		O
56	MRI in clinical trials. , 0, , 264-270.		0